Genetic predisposition to immune cell profiles and ischemic stroke risk: A Mendelian randomization study with implications for therapeutic targeting
JOURNAL/rmrep/04.03/02273995-990000000-00048/figure1/v/2026-11-18T080612Z/r/image-tiff Objectives: Ischemic stroke (IS) remains a leading cause of death and disability, and the causal role of specific immune cell phenotypes in its etiology is not fully understood. We aimed to identify genetically determined immune cell profiles causally associated with IS risk using a Mendelian randomization (MR) approach. Methods: Summary-level genetic data were obtained from publicly available genomewide association studies in this two-stage MR study. The exposure data originated from a genome-wide association study of 731 immune cell traits in 3757 Europeans. The outcome data for IS were derived from the UK Biobank (484,121 participants; 11,929 cases, 472,192 controls) and, for replication, from the FinnGen Consortium (212,774 participants; 10,551 cases, 202,223 controls). Genetic instruments for 731 immune phenotypes were selected at a significance threshold of P < 1 × 10 −5 , clumped for linkage disequilibrium ( r ² < 0.1, 500-kb window), and assessed for instrument strength (F-statistic > 10). The primary outcome was the IS (all subtypes). Causal effects were estimated using inverse variance weighting, with weighted median and MR-Egger regression used for sensitivity analyses. Heterogeneity (Cochran’s Q ) and horizontal pleiotropy (MR-Egger intercept) were tested. Results: In the discovery phase (UK Biobank), 33 immune traits were nominally associated with IS risk ( P < 0.05). Five traits were consistently replicated in FinnGen. Genetically predicted higher CD25hi CD45RA-CD4 + non-Treg %T cells were associated with increased IS risk (UKB: odds ratio (OR) = 1.022, 95% confidence interval (CI): 1.002–1.042, P = 0.028; FinnGen: OR = 1.031, 95% CI: 1.008–1.054, P = 0.008). Conversely, a reduced IS risk was associated with a higher CD33br HLA-DR + CD14 absolute count (UKB: OR = 0.983, 95% CI: 0.971–0.995, P = 0.004; FinnGen: OR = 0.984, 95% CI: 0.970–0.998, P = 0.020), higher herpesvirus entry mediator expression on CD45RA CD4 + cells (UKB: OR = 0.985, 95% CI: 0.972–0.998, P = 0.025; FinnGen: OR = 0.970, 95% CI: 0.941–0.999, P = 0.048), and higher C-C chemokine receptor type 7 expression on naive CD8br T cells (UKB: OR = 0.964, 95% CI: 0.938–0.990, P = 0.007; FinnGen: OR = 0.960, 95% CI: 0.924–0.997, P = 0.036), and CD16 expression on CD14 + CD16 + monocytes (UKB: OR = 0.976, 95% CI: 0.957–0.996, P = 0.016; FinnGen: OR = 0.965, 95% CI: 0.932–0.999, P = 0.041). No significant heterogeneity or horizontal pleiotropy was detected (all P > 0.05). Conclusions: These results reveal critical immunogenetic mechanisms driving IS pathology while highlighting distinct immune cell populations as promising candidates for therapeutic intervention, which offers dual potential in preemptive measures and tailored post-stroke immunomodulation approaches that ultimately enhance patient outcomes.
Authors
- Chunrun Qu (ORCID: https://orcid.org/0000-0003-4417-0864)
- Haiwei Geng
- Meixiang Liu (ORCID: https://orcid.org/0009-0007-9845-4519)
- Xuelun Zou (ORCID: https://orcid.org/0000-0002-5782-5463)
- 刘辉
- Ming Xie (ORCID: https://orcid.org/0000-0002-7766-2366)
- Bingbing Ge
- Han Li
- Haoliang Liu
- Shu Li
Institutions
- Central South University (CN)
- University of Oxford (GB)
- Ludwig Cancer Research (GB)
- Xinxiang Central Hospital (CN)
- Xiangya Hospital Central South University (CN)
Publication Details
- Journal
- Regenerative medicine reports .
- Published
- 2026-11-19
- DOI
- https://doi.org/10.4103/regenmed.regenmed-d-25-00044
- Primary Topic
- Genetic Associations and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 0.00